Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: Case report

Clinical Infectious Diseases

Volumn 45, Issue 12, 2007, Pages 1588-1590

  Vyas, Jatin M ^a   Telford, Sam R ^b   Robbins, Gregory K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIEMETIC AGENT; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; LAMIVUDINE; NELFINAVIR; PROBENECID; QUININE; STAVUDINE; ATOVAQUONE PROGUANIL; ATOVAQUONE-PROGUANIL; PROGUANIL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ANAMNESIS; ANOREXIA; ARTICLE; BABESIA MICROTI; BABESIOSIS; CASE REPORT; CHILL; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COUGHING; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE TRANSFUSION; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITAL READMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFECTION PREVENTION; KAPOSI SARCOMA; LABORATORY TEST; LETHARGY; LYME DISEASE; MALE; MONOTHERAPY; PARASITEMIA; PHYSICAL EXAMINATION; PNEUMOCYSTOSIS; PRIORITY JOURNAL; SIDE EFFECT; TICK; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; WEAKNESS; WEIGHT REDUCTION; WESTERN BLOTTING; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; IMMUNE DEFICIENCY; IMMUNOLOGY; MIDDLE AGED;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ATOVAQUONE; BABESIA MICROTI; BABESIOSIS; CHLOROGUANIDE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED;

EID: 40449110695     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/523731     Document Type: Article

References (17)

1. Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000; 343:1454-8.
2. Falagas ME, Klempner MS. Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin. Clin Infect Dis 1996; 22:809-12.
3. Froberg MK, Dannen D, Bakken JS. Babesiosis and HIV. Lancet 2004; 363:704.
4. Machtinger L, Telford SR 3rd, Inducil C, Klapper E, Pepkowitz SH, Goldfinger D. Treatment of babesiosis by red blood cell exchange in an HIV-positive, splenectomized patient. J Clin Apheresis 1993; 8: 78-81.
5. Weiss LM. Babesiosis in humans: a treatment review. Exp Opin Pharmacother 2002; 3:1109-15.
6. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089-134.
7. Dorman SE, Cannon ME, Telford SR 3rd, Frank KM, Churchill WH. Fulminant babesiosis treated with clindamycin, quinine, and wholeblood exchange transfusion. Transfusion 2000; 40:375-80.
8. Powell VI, Grima K. Exchange transfusion for malaria and Babesia infection. Transfus Med Rev 2002; 16:239-50.
9. Hogh B, Clarke PD, Camus D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Lancet 2000; 356:1888-94.
10. Fidock DA, Wellems TE. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A 1997; 94:10931-6.
11. Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999; 43:1334-9.
12. Krause PJ, Spielman A, Telford SR 3rd, et al. Persistent parasitemia after acute babesiosis. N Engl J Med 1998; 339:160-5.
13. Stowell CP, Gelfand JA, Shepard J-AO, Kratz A. Case 17-2007 - a 25-year-old woman with relapsing fevers and recent onset of dyspnea. N Engl J Med 2007; 356:2313-9.
14. Igarashi I, Suzuki R, Waki S, et al. Roles of CD4+ T cells and gamma interferon in protective immunity against Babesia microti infection in mice. Infect Immun 1999; 67:4143-8.
15. Aguilar-Delfin I, Wettstein PJ, Persing DH. Resistance to acute babesiosis is associated with interleukin-12- and gamma interferon-mediated responses and requires macrophages and natural killer cells. Infect Immun 2003; 71:2002-8.
16. Mavilio D, Lombardo G, Benjamin J, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A 2005; 102:2886-91.
17. Clawson ML, Paciorkowski N, Rajan TV, et al. Cellular immunity, but not gamma interferon, is essential for resolution of Babesia microti infection in BALB/c mice. Infect Immun 2002; 70:5304-6.